Scientific exchange · Dr. Hiroshi Weber

17 Aug 2026 · In person · Dr. Hiroshi Weber, Princess Margaret Cancer Centre · MSL James Whitfield · Lumeva

ReviewedVeeva CRMENG-0221—

Capture insight from this engagement

Location: Princess Margaret Cancer Centre
Therapeutic area: Neurology
Country: Canada
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Lumeva (lumevarin)

Topics discussed

Switching between CGRP agents
Dosing in hepatic impairment
Medication-overuse headache

Scientific content used

CGRP class review
LMV persistence data summary

Questions raised

Is there guidance on switching from a monoclonal antibody?

Notes

Scientific exchange with primary care physician at Princess Margaret Cancer Centre. Discussed switching between cgrp agents, dosing in hepatic impairment, medication-overuse headache.

Insights captured (1)

Capture insight

INS-0045Medium
Switching between CGRP agents
Switching between CGRP agents: recurring question reported by primary care physician (CA).
Prioritised

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 2
Depth of exchange: 4
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0221

Audit history (0)

All create, update and approval events for this record

No audit events in sample data